https://www.selleckchem.com/pr....oducts/apoptozole.ht
Building on our previously-reported novel tricyclic topoisomerase inhibitors (NTTIs), we disclose the discovery of REDX07965, which has an MIC90 of 0.5 μg mL-1 against Staphylococcus aureus, favourable in vitro pharmacokinetic properties, selectivity versus human topoisomerase II and an acceptable toxicity profile. The results herein validate a rational design approach to address the urgent unmet medical need for novel antibiotics.The alarming reduction in drug effectiveness against bacterial infections has created an urgent need for
Curtir
Comentario
Compartilhar
